US10932704B2ActiveUtilityA1
Device and method for measuring blood oxygen level and/or detecting brain hematoma
Est. expiryNov 14, 2034(~8.4 yrs left)· nominal 20-yr term from priority
A61B 5/14553A61B 5/4064A61B 5/14551A61B 5/0059A61B 5/7235A61B 5/6803
42
PatentIndex Score
0
Cited by
12
References
9
Claims
Abstract
A device for measuring brain oxygen level of a subject, including a probe (210) and a detecting means (220), which are respectively coupled to a processor (230). According to the example, the probe (210) includes three light sources (215a, 215b, 215c) that simultaneously emit the first, second, and third NIR wavelengths across the brain of the subject. The first NIR wavelength is the isosbestic wavelength for oxy-hemoglobin (HbO2) and deoxy-hemoglobin (Hb), the second NIR wavelength is shorter than the first NIR wavelength, and the third NIR wavelength is longer than the first NIR wavelength. The detecting means (220) includes a first, second and third detectors (221, 222, 223) for respectively detecting the NIR intensities of the first, second and third NIR wavelengths traveled across the brain. The processor (230) is configured to determine blood oxygen level based on the measured NIR intensities of the first, second and third NIR wavelengths by use of build-in algorithm derived from Beer-Lambert Law. And method of detecting brain hematoma of a subject by use of the present device.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A device for determining brain oxygen level and/or monitoring a brain hematoma in a subject, comprising,
a probe comprising a first, a second, and a third light sources configured to respectively emit a first, a second, and a third near infrared (NIR) wavelengths across the brain of the subject simultaneously, wherein the first, second and third NIR wavelengths are respectively about 790-810 nm, 650-790 nm, and 810-1,000 nm;
a detecting means comprising a first, a second, and a third NIR detectors, wherein each of the NIR detectors is configured to respectively measure a first, a second, and a third intensities of the first, second, and third NIR wavelengths after being transmitted across the brain of the subject;
a processor coupled to the probe and the detecting means, and is configured to determine the brain oxygen level or analyze the brain hematoma based on the first, second, and third intensities detected by the detecting means; and
a headset for wearing on the head of the subject, comprising,
a circular track-like structure for mounting the probe and the detecting means thereon, wherein the probe and the detecting means are disposed at opposite sides of the circular track-like structure thereby are spaced apart by 180 degrees; and
a driving means disposed on the circular track-like structure and coupled to the probe and the detecting means for driving the probe and the detecting means to move synchronously on the circular track-like structure in a direction that is parallel to the headset.
2. The device of claim 1 , wherein the first, second and third NIR wavelengths are respectively set at about 808 nm, 780 nm, and 850 nm.
3. The device of claim 1 , wherein each of the first, second, and third light sources is a laser diode (LD) or a light emitting diode (LED).
4. The device of claim 1 , wherein the probe is in the form of a tube with the first, second, and third light sources disposed at one end therein.
5. The device of claim 1 , wherein the brain oxygen level is determined by equations (1) and (2),
R
i
=
log
(
l
i
l
0
)
,
i
=
1
,
2
,
3
,
(
1
)
[
R
1
R
2
R
3
]
=
[
ϵ
Hb
(
λ
1
)
L
ϵ
Hb
O
2
(
λ
1
)
L
1
ϵ
Hb
(
λ
2
)
L
ϵ
Hb
O
2
(
λ
2
)
L
1
ϵ
Hb
(
λ
3
)
L
ϵ
Hb
O
2
(
λ
3
)
L
1
]
[
[
Hb
]
[
Hb
O
2
]
G
]
,
(
2
)
wherein I 0 and I respectively represent an intensity of NIR wavelength emitted from the light source and the intensity of NIR wavelength measured by the NIR detector, R is a logarithm of a ratio of I and I 0 , λ is the NIR wavelength, ∈ is an extinction coefficient of Hb or HbO 2 , L is an optical path length of the NIR wavelength, and G is an absorption coefficient.
6. The device of claim 1 , wherein the headset is configured to be adjustably fit on the head of the subject.
7. A method of determining brain oxygen level in a subject by using the device of claim 1 , comprising:
(a) placing the headset on the head of the subject;
(b) measuring the first, second, and third intensities of the first, second, and third NIR wavelengths after being transmitted across the brain of the subject by each of the first, second, and third NIR detectors of the detecting means; and
(c) determining the brain oxygen level of the subject based on the measured first, second, and third intensities of the step (b) using equations (1) and (2):
R
i
=
log
(
l
i
l
0
)
,
i
=
1
,
2
,
3
,
(
1
)
[
R
1
R
2
R
3
]
=
[
ϵ
Hb
(
λ
1
)
L
ϵ
Hb
O
2
(
λ
1
)
L
1
ϵ
Hb
(
λ
2
)
L
ϵ
Hb
O
2
(
λ
2
)
L
1
ϵ
Hb
(
λ
3
)
L
ϵ
Hb
O
2
(
λ
3
)
L
1
]
[
[
Hb
]
[
Hb
O
2
]
G
]
,
(
2
)
wherein I 0 and I respectively represent an intensity of NIR wavelength emitted from the light source and the intensity of NIR wavelength measured by the NIR detector, R is a logarithm of a ratio of I and I 0 , λ is the NIR wavelength, ∈ is an extinction coefficient of Hb or HbO 2 , L is an optical path length of NIR wavelength, and G is an absorption coefficient.
8. A method of monitoring a brain hematoma in a subject by using the device of claim 1 , comprising:
(a) placing the headset on the head of the subject;
(b) measuring the first, second, and third intensities of the first, second, and third NIR wavelengths after being transmitted across the brain of the subject by each of the first, second, and third NIR detectors of the detecting means; and
(c) comparing the measured first, second, and third intensities of the first, second, and third NIR wavelengths obtained from the step (b) with those of a healthy subject, and if the measured first, second, and third intensities of the first, second, and third NIR wavelengths are different from those of the healthy subject, then the subject has the brain hematoma.
9. The method of claim 8 , wherein the brain hematoma is located at the basal ganglia, the frontal lobe, the parietal lobe, the occipital lobe, the temporal lobe, or the cerebellum.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.